Grifols achieved EU permit to market Alzheimer’s test. Arachlon BiotechnologyA subsidiary of Grifols has received the CE marking for two early detection tests. disease Alzheimer’s ABtest-MS and ABtest-IA are their names First tests developed by a Spanish company For measurement of amyloid peptides in the blood to help assess the risk of developing Alzheimer’s disease. They receive this certificate, which is valid in all countries of the European Union, Iceland, Liechtenstein and Norway. This diagnostic method is a significant advance when it comes to taking measures to mitigate the effects of this devastating disease.
Using mass spectrometry (ABtest-MS) or with the ELISA technique (ABtest-IA), both tests allow the quantification of Aβ40 and Aβ42 proteins in biological samples in relation to the risk of developing Alzheimer’s disease. Currently, two tests are available through the ABtestService for plasma samples in the case of ABtest-MS and for plasma and cerebrospinal fluid (CSF) in the case of ABtest-IA, but it means obtaining permission from European inspectors. Go one step further in standard clinical routines with a reliable, minimally invasive, highly agile and less costly detection tool, according to Grifols’ assessment.
Arachlon Biotechnology He specializes in the research and development of treatment and diagnostic methods for Alzheimer’s disease. The use of these plasma tests allows doctors to have a new pre-selection criterion (triage) and significantly reduces the cost of recruiting people to participate in clinical trials of new treatments.
Recent studies, the results of which were presented at international congresses, have demonstrated the high predictive capacity of ABtest-MS to accurately identify patients with cerebral amyloid burden, a hallmark of Alzheimer’s in the very early stages. ABtest-IA also showed a close relationship between plasma β-amyloid protein levels and amyloid deposition in the brain. Both tests allow for the identification of higher levels of risk in progression to dementia. These tests are integrated into studies looking for remedies and treatments for the disease. A clinical trial called Ambar is in Phase III, the final phase before reaching an effective drug.